Shareholders of Luminex Corporation (NASDAQ:LMNX) have seen a range-bound movement in the stock over the years. In 2013 LMNX underperformed the overall market, particularly the biotech sector, due to the fact that the life science research and the molecular diagnostic markets were experiencing a temporary deceleration. However, 2014 is looking like a big year for LMNX, with the company's advanced xMAP, xTAG and MultiCode technologies gaining momentum. Moreover, the company has a healthy pipeline including Project ARIES, its next-generation integrated molecular diagnostics system that is expected to be rolled out in 2014.
While the company would continue to face some risks associated with the underutilization of molecular assays due to budget sequestration in the United States, particularly in...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|